The frequency imperative.

Timing can matter as much as sensitivity.

LBx Bio is developing a compact biomarker monitoring platform designed to increase surveillance cadence in the intervals between centralized lab tests — surfacing rising molecular signals earlier, then routing them into timely confirmatory testing through existing clinical workflows.

We are beginning in oncology, where earlier visibility into recurrence could accelerate follow-up and care decisions.